These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

773 related articles for article (PubMed ID: 18479258)

  • 1. NF-kappaB in inflammatory bowel disease.
    Atreya I; Atreya R; Neurath MF
    J Intern Med; 2008 Jun; 263(6):591-6. PubMed ID: 18479258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial NEMO links innate immunity to chronic intestinal inflammation.
    Nenci A; Becker C; Wullaert A; Gareus R; van Loo G; Danese S; Huth M; Nikolaev A; Neufert C; Madison B; Gumucio D; Neurath MF; Pasparakis M
    Nature; 2007 Mar; 446(7135):557-61. PubMed ID: 17361131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of nuclear factor-kappaB in dogs with chronic enteropathies.
    Luckschander N; Hall JA; Gaschen F; Forster U; Wenzlow N; Hermann P; Allenspach K; Dobbelaere D; Burgener IA; Welle M
    Vet Immunol Immunopathol; 2010 Feb; 133(2-4):228-36. PubMed ID: 19740552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
    Sartor RB
    Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New mediators of immunity and inflammation in inflammatory bowel disease.
    Monteleone G; Fina D; Caruso R; Pallone F
    Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis.
    De Vry CG; Prasad S; Komuves L; Lorenzana C; Parham C; Le T; Adda S; Hoffman J; Kahoud N; Garlapati R; Shyamsundar R; Mai K; Zhang J; Muchamuel T; Dajee M; Schryver B; McEvoy LM; Ehrhardt RO
    Gut; 2007 Apr; 56(4):524-33. PubMed ID: 16950831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in biological therapy for inflammatory bowel disease.
    Kurtovic J; Segal I
    Trop Gastroenterol; 2004; 25(1):9-14. PubMed ID: 15303463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear factor-kappa B in intestinal protection and destruction.
    Spehlmann ME; Eckmann L
    Curr Opin Gastroenterol; 2009 Mar; 25(2):92-9. PubMed ID: 19528876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease.
    Shioya M; Nishida A; Yagi Y; Ogawa A; Tsujikawa T; Kim-Mitsuyama S; Takayanagi A; Shimizu N; Fujiyama Y; Andoh A
    Clin Exp Immunol; 2007 Sep; 149(3):480-6. PubMed ID: 17590175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of NF-kappaB activation in intestinal immune homeostasis.
    Wullaert A
    Int J Med Microbiol; 2010 Jan; 300(1):49-56. PubMed ID: 19781989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy.
    Fiocchi C
    Minerva Gastroenterol Dietol; 2002 Sep; 48(3):215-26. PubMed ID: 16491045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance.
    Caradonna L; Amati L; Magrone T; Pellegrino NM; Jirillo E; Caccavo D
    J Endotoxin Res; 2000; 6(3):205-14. PubMed ID: 11052175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases.
    Sartor RB
    Am J Gastroenterol; 1997 Dec; 92(12 Suppl):5S-11S. PubMed ID: 9395346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
    Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe?
    Reuter BK; Pizarro TT
    Eur J Immunol; 2004 Sep; 34(9):2347-55. PubMed ID: 15307167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunology of inflammatory bowel diseases.
    Lakatos L
    Acta Physiol Hung; 2000; 87(4):355-72. PubMed ID: 11732889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives.
    Neurath MF
    Arch Immunol Ther Exp (Warsz); 2000; 48(2):81-4. PubMed ID: 10807047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [NF-kappa B and inflammatory intestinal diseases].
    Nosti-Escanilla MP; Peña AS
    Rev Esp Enferm Dig; 1998 Feb; 90(2):113-9. PubMed ID: 9580438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling for inflammation and repair in inflammatory bowel disease.
    Neuman MG
    Rom J Gastroenterol; 2004 Dec; 13(4):309-16. PubMed ID: 15624029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological disorders in inflammatory bowel disease and immunotherapeutic implications.
    Amati L; Caradonna L; Jirillo E; Caccavo D
    Ital J Gastroenterol Hepatol; 1999 May; 31(4):313-25. PubMed ID: 10425578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.